Liver Cancer Treatment in China: What Function Changes, What NanoKnife Ads Don't
Most liver-cancer files in China are HBV-related HCC plus liver-function math. IARC 2024: 354,143 new cases and 303,783 deaths. CARES-310 reported OS 23.8 vs 15.2 months for a China-approved combination. Transplant is not a tourist product. Send triphasic imaging and Child-Pugh labs. About 24 hours. No obligation to book.
Average reply: 24 hoursNo obligation to book
HBV + functionnot a logo
OS 23.8 vs 15.2CARES-310
No tourist transplantallocation rules
Quick answer
Most liver-cancer files in China are HBV-related HCC plus liver-function math. IARC GLOBOCAN 2024: 354,143 new cases and 303,783 deaths (second after lung). Ablation is for selected small tumours, not a chemo substitute. Transplant is not a tourist product. CARES-310 (camrelizumab plus rivoceranib vs sorafenib) reported OS 23.8 vs 15.2 months — a China-approved first-line combination, not an FDA-interchangeable guarantee. Send triphasic imaging and Child-Pugh labs. About 24 hours. No obligation to book.
Liver: method follows function
On the table after labs
Resection, ablation, TACE/TARE, systemic targeted/IO, selected particle therapy.
Not a tourist SKU
Transplant is policy, not a package. CAR-T is not standard HCC care.
| Question | Usual comparison | Cost note |
|---|---|---|
| Resectable / high-volume HCC | SYSUCC, Shanghai hepatobiliary, CAMS/NCC, Tianjin | OR + function risk — no single band |
| Repeat TACE vs systemic switch | Same public liver units | Session fees vs months of drugs |
| Selected proton / carbon-ion | SPHIC if indication + imaging | ~USD 20-35k course if accepted |
| Fuda name already on the file | Compare method with SYSUCC | Brand is not a price |
What actually changes the plan
📋
Function and burden first
Child-Pugh, portal vein, lesion map, AFP. Without that, every hospital letter is a guess.
🏥
Hepatobiliary volume, not a brand
SYSUCC, Shanghai units, CAMS/NCC, Tianjin. SPHIC only if a beam is the actual question.
✈️
Method-shaped costs
TACE days, systemic months, or a proton calendar. We refuse one HCC package number.
What this page helps you decide
✅
Transplant not sold as tourism
If it is even discussable, it is a policy question, not a landing-page SKU.
💬
Local vs systemic labelled
Ablation/TACE and IO/targeted drugs are different bills and different goals.
🌍
Fuda compared with public liver units
Brand search volume is not liver-function math.
Evidence table
IARC liver deaths, CARES-310 OS, NCCN ablation limits, transplant is not tourism.
| Source | What it says | Relevance to patients |
|---|---|---|
| IARC GLOBOCAN China (2024) | 354,143 cases; 303,783 deaths | HBV-endemic burden. Not a package price. |
| CARES-310, Lancet Oncol (2025 final) | OS 23.8 vs 15.2 months; PFS 5.6 vs 3.7; HR 0.64 | China-approved combo. Hypertension and transaminase toxicity. |
| NCCN ablation notes (current) | Selected small HCC | Not IRE-for-everything. |
| FDA CRLs on the same combo (through 2026) | US file not interchangeable | China label ≠ US label. |
Who this page is for
HCC after several TACE sessions
Need a systemic or particle question answered, not another unnamed embolisation package.
Potentially resectable patients
Need a high-volume hepatobiliary opinion on function and margin, not a brand tour.
Families asking about transplant in China
Need a no-package answer first, then whatever policy path actually exists.
What you can actually book
SYSUCC, Fudan / Eastern Hepatobiliary / Zhongshan, CAMS/NCC. Compare any private local method with a public hepatobiliary unit. Related: Fuda, cancer hub.
What moves the cost
Liver file review
No charge to start
Function/burden read • Method label • Centre shortlist • Transplant honesty
Coordinated trip
Quoted after records
Hospital matching • Method-shaped drivers • Visa • Interpreter
These are routing steps, not a hospital package SKU. Published procedure examples stay in the evidence/cost sections only when a source exists. Hospital, drugs, stay, interpreter and travel are quoted separately after records.
What happens next
01
Send imaging and liver labs
Plus viral status and prior locoregional/systemic history.
02
Label resectable vs locoregional vs systemic
And say when particle therapy is a real question vs noise.
03
Travel after a liver unit accepts
Invitation, visa, interpreter. Repeat TACE calendars need a longer stay plan.
Request a preliminary case review
Tell us the basics of your case. When you submit, WhatsApp will open with the information you entered so you can review it before sending. This is a preliminary routing request, not a diagnosis, treatment acceptance, trial enrollment, visa decision, or medical advice.
Frequently asked questions
How much is liver cancer treatment in China?
Ablation, TACE, systemic combinations and transplant are different invoices. CARES-310 drugs are a China-labelled option for unresectable HCC, not a flyer price. We itemise after function and stage.
What is CARES-310?
Phase 3 camrelizumab plus rivoceranib vs sorafenib. Final OS 23.8 vs 15.2 months; PFS 5.6 vs 3.7. Approved in China for first-line unresectable HCC. Not an FDA-interchangeable guarantee.
Is NanoKnife standard?
Often investigational or highly selected. Not a pan-HCC substitute.
Can foreigners get a liver transplant in China?
Transplant exists under organ-allocation rules. It is not a standard self-pay walk-in product. We will not sell it as one.
Which hospitals?
SYSUCC, Fudan/Eastern Hepatobiliary/Zhongshan, CAMS/NCC.
What records should I send?
Triphasic CT or MRI, HBV/HCV serology, Child-Pugh labs, AFP, prior TACE dates.
Is Fuda the default liver hospital?
No. Compare any private local method with a public hepatobiliary unit.
Do you promise AFP will fall?
No. Average reply about 24 hours. No obligation to book.
Do I pay before you read the file?
No. Payment required before a file review is a red flag. Average reply about 24 hours. No obligation to book.
How fast do you reply?
About 24 hours. We label the file as labelled care, trial, or marketing. No obligation to book.
Red flags in offers
NanoKnife or cryo as the China liver trip, often via Fuda marketing. Transplant sold as walk-in self-pay. Neither is the usual honest desk.
Ablation sold for portal-vein tumour thrombus as a cure.
Transplant quoted as a tourism SKU.
No Child-Pugh, no HBV status on the offer.
Pay before triphasic CT/MRI is read.
Sources
IARC GLOBOCAN 2024 China fact sheet.
Qin et al., CARES-310 final analysis, Lancet Oncology 2025.
NCCN ablation notes; BCLC-style function logic.
Public descriptions of SYSUCC, Fudan/EHBH, CAMS/NCC.
A treating hepatologist or oncologist should review imaging before you travel. This page is matching information, not a treatment recommendation.
Freshness label on this page: 2026-08-15